The Low-Grade Glioma drugs in development market research report provides comprehensive information on the therapeutics under development for Low-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Low-Grade Glioma. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Low-Grade Glioma - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Low-Grade Glioma and features dormant and discontinued products.

GlobalData tracks 28 drugs in development for Low-Grade Glioma by 23 companies/universities/institutes. The top development phase for Low-Grade Glioma is phase ii with 13 drugs in that stage. The Low-Grade Glioma pipeline has 26 drugs in development by companies and two by universities/ institutes. Some of the companies in the Low-Grade Glioma pipeline products market are: Novartis, Les Laboratoires Servier and Pfizer.

The key targets in the Low-Grade Glioma pipeline products market include Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2), Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2), and Isocitrate Dehydrogenase [NADP] Cytoplasmic (Oxalosuccinate Decarboxylase or Cytosolic NADP Isocitrate Dehydrogenase or IDP or NADP(+) Specific ICDH or IDH1 or EC 1.1.1.42).

The key mechanisms of action in the Low-Grade Glioma pipeline product include Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Inhibitor with seven drugs in Phase II. The Low-Grade Glioma pipeline products include nine routes of administration with the top ROA being Oral and five key molecule types in the Low-Grade Glioma pipeline products market including Small Molecule, and Subunit Vaccine.

Low-Grade Glioma overview

Low-grade gliomas are benign grade 1 and grade 2 tumors of the brain or spinal cord, according to WHO classification. The development of these tumors may be brought on by environmental variables or genetic abnormalities. The tumor’s size and location affect how it presents itself. Main causes include genetic mutations or environmental factors. Usually seizure is the first sign of a low-grade glioma.

For a complete picture of Low-Grade Glioma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.